[1] |
LIN Yicong, WANG Yue, XUE Qianqian, ZHENG Qiang, JIN Yan, HUANG Ziling, LI Yuan.
Clinical pathological characteristics and immune microenvironment significance of EGFR T790M mutation in non-small cell lung cancer patients and its prognostic implications
[J]. China Oncology, 2024, 34(4): 368-379.
|
[2] |
China Anti-Cancer Association Tumor Biomarker Professional Committee, Shanghai Anti-Cancer Association Tumor Biomarker Professional Committee.
Expert consensus on population-based BRCA germline mutation screening in China (2024 edition)
[J]. China Oncology, 2024, 34(2): 220-238.
|
[3] |
LI Jun, LU Tingwei, FANG Xuqian.
Impact of MSI-H/dMMR on clinicopathological characteristics and prognosis of patients with BRAF V600E-mutated resectable colorectal cancer
[J]. China Oncology, 2024, 34(11): 1061-1066.
|
[4] |
ZHAO Bolun, ZHU Guannan.
Advances in the treatment of advanced melanoma with NRAS gene mutation
[J]. China Oncology, 2023, 33(10): 936-944.
|
[5] |
HE Liyuan, WANG Yudong.
Research progress of ALK kinase domain drug resistance mutation and its future countermeasures
[J]. China Oncology, 2022, 32(8): 736-746.
|
[6] |
DENG Shuting, FENG Yuan, QIAN Kai, GUO Kai, WANG Zhuoying.
Meta-analysis of the association between gene alterations and distant metastasis of differentiated thyroid carcinoma in children and adolescents
[J]. China Oncology, 2022, 32(5): 388-396.
|
[7] |
JIANG Jianyun, YING Hongmei.
Clinical research progress in the treatment of BRAF V600 mutation-positive advanced melanoma
[J]. China Oncology, 2022, 32(5): 445-450.
|
[8] |
LI Ting, XU Yu, JIA Dongdong, LIAO Zhichao, SUN Wei, WU Haixiao, REN Zhiwu, ZHAO Jun, XING Ruwei, TENG Sheng, YANG Yun, CHEN Yong, LI Tao, YANG Jilong.
Adjuvant therapy with anti-PD-1 antibody vs targeted therapy for patients with resected stage Ⅲ malignant melanoma: a real-world data analysis from China centers
[J]. China Oncology, 2022, 32(12): 1147-1157.
|
[9] |
SHI Yue, CHEN Yiqing, DING Jingxin, NING Yan, WANG Qing, MA Fenghua, TAN Haowen, KANG Yu.
Questionnaire survey on current status of clinical screening and treatment of gynecological disease in females with Peutz-Jeghers syndrome
[J]. China Oncology, 2022, 32(11): 1049-1064.
|
[10] |
PENG Zishan, KONG Hui, BAO Zhen, ZHAO Hongxing, LIU Xin, LU Shaohua.
Clinicopathological analysis of 83 cases of multifocal lung adenocarcinoma
[J]. China Oncology, 2021, 31(5): 408-418.
|
[11] |
ZHAO Yuanyuan , ZHOU Jianying , FAN Yun , WANG Jialei , HUANG Dingzhi , LI Junling , SHI Meiqi , LIU Jiwei , YAO Yu , WU Lin , YAO Wenxiu , ZHANG Li .
Advances in the treatment of BRAF V600-mutant non-small cell lung cancer
[J]. China Oncology, 2021, 31(12): 1145-1152.
|
[12] |
HE Xi, JIAO Xiaodong, ZANG Yuansheng.
Clinical research progress of tumor mutational burden in EGFR-mutant advanced non-small cell lung cancer
[J]. China Oncology, 2021, 31(1): 69-75.
|
[13] |
CHEN Xinning , WANG Beili , GUO Wei .
Impact of clonal hematopoiesis on the detection of somatic mutation
[J]. China Oncology, 2020, 30(9): 707-711.
|
[14] |
ZHU Lihua , NI Tingting , FAN Xingwen , WU Kailiang .
Comparison of prognostic scoring systems in patients with EGFR-mutant lung cancer and brain metastases
[J]. China Oncology, 2020, 30(8): 605-610.
|
[15] |
REN Chunxia,XIA Xiaoai,YANG Shudong,LV Bei,TONG Guoqing .
Establishment and initial analysis of an immortalized human ovarian surface epithelial cell line carrying a BRCA1 mutation
[J]. China Oncology, 2019, 29(9): 693-699.
|